TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19

Benzinga · 3d ago
TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $18 to $19.